We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Shilpa Gupta

Shilpa Gupta MD

Genitourinary Oncologist, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Dr. Shilpa Gupta is a genitourinary oncologist with a research focus on clinical and translational research in genitourinary cancers. Prior to joining the Cleveland Clinic in June 2019, Dr. Gupta was an associate professor at the University of Minnesota where she led the phase I interdisciplinary Solid Tumor Program and Genitourinary Oncology Research. 

Dr. Gupta obtained her medical degree at the Lady Hardinge Medical College in New Delhi, India, after which she completed a fellowship in emergency medicine through the Royal College of General Practitioners in the UK. She went on to do residency training in internal medicine at the University of Connecticut, and she completed a hematology/oncology fellowship at Georgetown University and Thomas Jefferson University. She then pursued a genitourinary translational research fellowship at Thomas Jefferson. Dr. Gupta is widely published and has presented her work at several national and international forums. She is a member of the American Urologic Association, Society of Urologic Oncology, European Society for Medical Oncology, American Association for Cancer Research, American Society of Clinical Oncology, and American Society of Hematology, among other professional organizations.

Recent Contributions to PracticeUpdate:

  1. Novel Targets for the Treatment of Bladder Cancer
  2. Key Takeaways From ESMO: Novel Frontline Therapies for Advanced Bladder Cancer
  3. Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
  4. Avelumab Maintenance for Advanced Urothelial Carcinoma
  5. Maintenance Therapy for Metastatic Urothelial Cancer
  6. Role of PD-L1 Testing in Urothelial Carcinoma
  7. ASCO: Combined Immunotherapy and Chemotherapy for Urothelial Carcinoma
  8. Bladder Cancer in the COVID Era: Metastatic Cancers and the Role of Clinical Trials
  9. Bladder Cancer in the COVID Era: Locally Advanced Muscle Invasive Cancer
  10. Bladder Cancer in the COVID Era: Non-Muscle Invasive Cancer

Most Read This Week

Recently Updated